Ossifix Orthopedics Begins Comparative Study

Umbra Applied Technologies Group Inc.’s (UAT Group) subsidiary Ossifix Orthopedics has begun a comparative study to compare previously available traditional methods and materials against the Ossifix Javelin allograft bone pin system. The trial will be conducted across six different sites.
 
Initial patients demonstrated early ambulation with patients driving the next day leading to patients being medically released an estimated 50% faster. The Javelin pin has shown to fully incorporate and become part of the existing bone without ossification. Patients were released around the four-week mark compared with the average eight to 10 weeks typically needed with traditional materials and processes.
 
Constructed of select, high-density, allograft, cortical bone, the proprietary design of the Ossifix Orthopedics Javelin pin ensures rigid fixation without pin slip or pirouetting. Ossifix will continue to build and expand upon this initial success by expanding to additional surgical centers.
 
“We are currently in the process of compiling and analyzing outcome data from surgical procedures done during the latter part of 2022. We will continue gathering data for the next few months and are expecting to compile data on approximately 120 patients in total,” Ossifix CEO Mark Estrada stated. “The study will report those outcomes from approximately 12 surgeons and compare the Javelin to competitive metallic product outcomes.”
 
Ossifix engineers and manufactures 100% allograft bone implants for small bone, extremities, and sports medicine markets, but its products can be used in craniofacial, spinal, and oral surgery procedures. Resorbable implant technology is readily accepted and used in today’s market, both domestically and globally. No regulatory approval is required for implantable fixation engineered from allograft bone. As a result, barriers to entry into the market for Ossifix Technologies implants are minimal.
 
Ossifixs’ unique manufacturing process and patent pending designs yield an engineered cortical bone implant that provides secure fixation and virtually eliminates any allergic or autoimmune reactions associated with metal or plastic/polymer implants. All Ossifix Orthopedics Pin, Screw and Plate Systems are single-use surgical kits with all necessary instruments for implantation and are based on decades of clinical experience and OR use. Instrumentation is constructed of an eco-friendly, bio-degradable polymer.
 
Ossifix products are designed to be used in hospitals, ambulatory surgical centers, and specialty clinics. Distribution is scheduled throughout North America, and globally in Latin America, Europe, Asia Pacific, as well as the Middle East and Africa. This global market is currently experiencing an estimated growth of 14% annually and is expected to reach $4.69 billion in sales this year.
 
“Now that the holidays are behind us, the Ossifix team has begun ramping up their sales and scheduled surgeries. I am encouraged with the progress they have made and look forward to the results of the comparative study,” UAT Group CEO Alex Umbra said. 
  
UAT Group is located in Spring Hill, Fla., and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries.